Log In
Print
BCIQ
Print
Print this Print this
 

PINTA 745 (formerly AMG 745)

  Manage Alerts
Collapse Summary General Information
Company Atara Biotherapeutics Inc.
DescriptionRecombinant Fc-peptide fusion protein
Molecular Target Myostatin (MSTN) (GDF8)
Mechanism of ActionMyostatin (GDF-8) inhibitor
Therapeutic ModalityBiologic: Fusion protein
Latest Stage of DevelopmentPhase II
Standard IndicationEnd-stage renal disease (ESRD)
Indication DetailsTreat patients with end-stage renal disease (ESRD) who are on hemodialysis and have protein energy wasting (PEW)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today